• Applications & Products
    • Applications
    • Products
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
      • Food Science
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Insulin-Transferrin Supplements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Human Lysozyme
      • Recombinant Human Interleukins
    • Products
      • Cellastim S® – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin® 20 – Recombinant human albumin
      • Optibumin® 25 – Recombinant human albumin
      • Optiferrin® – Recombinant human transferrin
      • Lacromin® – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac® – Recombinant human lysozyme
      • OptiLeukin 2 – Recombinant human IL-2
      • LIF – Leukemia Inhibitory Factor
      • OptiVERO® – Chemically-defined complete VERO media
  • About InVitria
  • News & Blog
  • Contact Us
  • Knowledge Base
  • Applications
  • Products
  • Contact Us
  • Home
  • Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Published on 27 March 2023

Exbumin® provides significant regulatory and quality benefits over other excipients, surfactants, and animal-derived reagents.

 Elliott Renft, Sofia Pezoa PhD, Marcus Curl

Introduction

Biological manufacturers face many challenges in downstream processing unit operations of viral based therapeutics that impact the integrity, stability, and potency of their final drug product. Human Serum Albumin (HSA) has been shown to improve yield during common downstream purification unit operations such as tangential flow filtration, depth filtration, chromatography, sterile filtration, and final formulation of viruses and viral vectors. However, the use of serum-derived proteins is discouraged due to supply chain and regulatory concerns as well as concern about potential to introduce adventitious agents.

Here we demonstrate that a recombinant excipient-grade albumin, known as Exbumin®, increases viral yields via virus stabilization during downstream purification unit operations as well as in final formulation while retaining consistency and safety of the final product. Taken together, incorporation of Exbumin® into downstream viral purification protocols can provide benefit for large scale cell/gene therapy and vaccine manufacturing.

Exbumin® Recombinant HSA (“rHSA”) has benefits, such as:

  • Recombinant – improved performance over native blood-sourced HSA
  • Sustainable – no animal origin components
  • Scalable – metric ton capacity removes supply chain concerns

Conclusion

Downstream processing holds many challenges for manufacturers, some of which include: preparing stable viral vectors, preventing degradation during manufacturing, handling and storage, and maintaining their long-term stability and efficacy. Albumin, among its many benefits, has been shown to significantly reduce vector and virus loss during downstream process unit operations. Recombinant Albumin (rHSA) is shown to consistently perform comparably, if not better, than native derived HSA. Exbumin® provides significant regulatory and quality benefits over other excipients, surfactants, and animal-derived reagents.

Virus-Yield-Improvement-Downstream-Processing-Exbumin-Excipient-Recombinant-AlbuminL Download PDF Here
Start New Search

Quick Search Links

Application:

Antibody Production

Cell Therapy

Final Formulation

Food Science

Gene Therapy

T-Cell Immunotherapy

Vaccine Production

Product Category:

Cell Culture Supplements

Albumin

Cell Culture Media

Interleukins

Lactoferrin

LIF

Lysozyme

Single Components

Transferrin

Product:

Exbumin® – Recombinant human albumin excipient

ITS AF™ – Blood-free cell culture media supplement

ITSE + A™ – Blood-free cell culture media supplement

ITSE Animal-Free® – Blood-free cell culture media supplement

Lacromin® – Recombinant human holo-lactoferrin

OptiLeukin™ 2 – Recombinant human interleukin-2

OptiVERO®

Cellastim® S – Recombinant human albumin

Optibumin ® 20 – Recombinant human albumin

Optibumin ® 25 – Recombinant human albumin

Optiferrin® – Recombinant human transferrin

Leukemia Inhibitory Factor

Lysobac® – Recombinant human lysozyme

Document Type:

Application Notes

Blog

Catalog

Data Sheets

Interviews

Journal Articles (DOI Links)

News

Posters

Product Brochures

Product Specifications

SDS

Use Guidelines

Webinar

White Papers

Cell Line:

B Lymphocyte

CHO

ESC

HEK293

Hematopoetic Stem Cells

Hybridoma

iPSC

Mesenchymal Stem Cells

Natural Killer Cells

Neural Stem Cells

T Lymphocyte

VERO

  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2025 InVitria

    • Terms
    • Privacy
    • Sitemap